Last reviewed · How we verify
Repaglinide, Bupropion and SHR3680 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Repaglinide, Bupropion and SHR3680 (Repaglinide, Bupropion and SHR3680) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Repaglinide, Bupropion and SHR3680 TARGET | Repaglinide, Bupropion and SHR3680 | Jiangsu HengRui Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Repaglinide, Bupropion and SHR3680 CI watch — RSS
- Repaglinide, Bupropion and SHR3680 CI watch — Atom
- Repaglinide, Bupropion and SHR3680 CI watch — JSON
- Repaglinide, Bupropion and SHR3680 alone — RSS
Cite this brief
Drug Landscape (2026). Repaglinide, Bupropion and SHR3680 — Competitive Intelligence Brief. https://druglandscape.com/ci/repaglinide-bupropion-and-shr3680. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab